Denosumab is a fully human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, bone metastases, multiple myeloma, and giant cell tumor of bone. It was developed by the biotechnology company Amgen.In June 2010, denosumab was approved by the U.S.
| Attributes | Values |
|---|---|
| rdfs:comment |
|
| ATC prefix |
|
| ATC suffix |
|
| CAS number |
|
| FDA UNII code |
|
| is product of |